Intelligence · Clinical Development
Pipeline search results
Programs matching “placebo” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.
Quick answer
Showing 588 pipeline programs matching "placebo" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.
Refine search
Search results
-
Bitopertin, Matching Placebo
Disc Medicine
X-Linked Protoporphyria (XLP), Erythropoietic Protoporphyria (EPP)
1 trial -
Cenerimod 4 mg, Cenerimod matching placebo
Viatris Pharmaceuticals Co.,
Moderate to severe systemic lupus erythematosus
1 trial -
Cenerimod matching placebo, Cenerimod 4 mg
Viatris Pharmaceuticals Co.,
Moderate to severe systemic lupus erythematosus
1 trial -
DAPAGLIFLOZIN, PLACEBO
Disc Medicine
Hypomagnesemia due to HNF1beta mutation
1 trial -
DAPAGLIFLOZIN, PLACEBO DE DAPAGLIFLOZIN 10 mg
Pari Pharma GmbH
Cardiac failure
1 trial -
Doxycycline (200mg/day) or Placebo
United Therapeutics Europe Ltd
Persian Gulf Syndrome
1 trial -
Dupilumab, Matched placebo for test product
Sanofi-aventis Healthcare Pty Ltd
Neurodermatitis
1 trial -
Dupilumab, Matched placebo for test product
Sanofi-aventis Healthcare Pty Ltd
Neurodermatitis
1 trial -
Duvakitug, Matched placebo for test product
Sanofi-aventis Healthcare Pty Ltd
Immune system diseases
1 trial -
Duvakitug, matched placebo for test product
Sanofi-aventis Healthcare Pty Ltd
Immune system diseases
1 trial -
Efgartigimod, Placebo for efgartigimod
argenx
Thyroid Eye Disease (TED)
1 trial -
Erenumab, Placebo for AMG 334
Amgen
Episodic Migraine
1 trial -
FAMPRIDINE, Placebo 515
Pari Pharma GmbH
Spinocerebellar ataxia
1 trial -
GLUCOPHAGE 500 mg tabletki powlekane, Placebo
Bial Portela & Companhia S.A.
papillary thyroid carcinoma
1 trial -
Galcanezumab, Placebo to match LY2951742
Eli Lilly Co.
Chronic Migraine
1 trial -
Galcanezumab, Placebo to match LY2951742
Eli Lilly Co.
Migraine
1 trial -
Glepaglutide 20.0 mg/mL, Glepaglutide Placebo
Zealand Pharma A/S
Short Bowel Syndrome
1 trial -
Icotrokinra, JNJ-77242113-AAC Placebo tablet
Janssen-Cilag International N.V.
Moderately to Severely Active Ulcerative Colitis
1 trial -
Itepekimab, Matched Placebo for test product
Sanofi-aventis Healthcare Pty Ltd
Chronic Obstructive Pulmonary Disease
1 trial -
Itepekimab, Matched placebo for test product
Sanofi-aventis Healthcare Pty Ltd
Chronic Obstructive Pulmonary Disease
1 trial -
Itepekimab, Matched placebo for test product
Sanofi-aventis Healthcare Pty Ltd
Chronic rhinosinusitis with nasal polyps
1 trial -
JNJ-77242113-AAC Placebo tablet, JNJ-77242113
Janssen-Cilag International N.V.
Active Psoriatic Arthritis
1 trial -
Lactose Placebo
United Therapeutics Europe Ltd
Elbow Fracture
1 trial -
Linaclotide or Matching Placebo
IRONWOOD PHARMACEUTICALS INC
Irritable Bowel Syndrome With Constipation
1 trial
Frequently asked questions
What is the Clinical Development Intelligence Platform?
It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.
How does this compare to Evaluate Pharma or Citeline?
Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.
Where does pipeline data come from?
Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.
Can I follow a company or program for updates?
Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.